Ultimovacs (ULTI) småprat 1

[polygon]

…eller en enda enklere analogi: UV1 er en rød klut, og CPIer et tupp i ræva på oksen

[h3nk1]

Radium med Sara Mangsbo (Chief Innovation Officer) publisert nå.

[polygon]

Hun blir såpass engasjert om UV1 sitt profylaktiske potensiale der på slutten, at Einarsson må stagge henne

[TekBot]

Ultimovacs ASA: Share capital increase related to exercise of options

Oslo, 12 October 2021, the Board of Directors of Ultimovacs ASA (the “Company”)
has resolved to increase the Company’s share capital by NOK 5,850 through the
issuance of 58,500 new shares, each with a par value of NOK 0.10. The resolution
…

Vis børsmeldingen

is based on an authorisation to increase the share capital granted by the
Company’s general meeting on 15 April 2021.

The new shares are issued to employees of the Company in connection with the
Company’s employee incentive program. 45,000 of the new shares are issued at a
subscription price of NOK 31.25, and 13,500 shares at a subscription price of
NOK 39.15.

Following registration of the share capital increase with the Norwegian Register
of Business Enterprises, the Company will have a share capital of NOK
3,206,176.10, divided into 32,061,761 shares, each with a par value of NOK
0.10.

For further information, please contact:

Jónas Einarsson, Chairman of the Board of Directors of Ultimovacs ASA
Email: je@radforsk.no
Phone: +47 480 96 355

Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507

Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632

Kilde

[Fornybar]

Vel unt.

[polygon]

Einarsson i dagens Radium om UV1 som profylaktisk(beskyttende) vaksine: “dette krever også at myndighetene går litt tungt inn og er med - det er ikke noe et sånt lite eller mellomstort selskap som kan satse… ta den store satsingen, men det jobbes med det, så det er en spennede utvikling….”

Er det kontakten med National Cancer Institute i USA han snakker om her (Ultimovacs Fundamentale forhold (ULTI) - #901 av polygon), eller er det dialog med norske myndigheter også?

Bare å forestille seg på hvilken måte norsk biotek (og norske politikere) blir satt på verdenskartet dersom regjeringen bevilger noen milliarder til å gjennomføre en stor langtids-studie i friske f.eks. kvinner med BRCA-mutasjoner! (bare gen-testingen i forkant og det datasettet man da ville fått, ville skapt internasjonal oppmerksomhet)

[HO5]

Er det ikke frameshift-mutasjoner og Hubro han tenker på da? Var min første tanke ihvertfall.
De har uttalt mål om profylaktisk vaksine til de med lynch syndrom. Veldig liten del av befolkningen (0,1%), men de som har syndromet har 80 % sannsynlighet for å utvikle kreft.

[polygon]

Både spørsmålet (som var mitt) og svarene, går på UV1. Hubro, frameshift-mutasjoner og lynch syndrom er nok ikke det de heller hadde i tankene.

Men det er veldig vanlig å tenke først på det selskapet man er investert i

[HO5]

Du har sikkert rett, men jeg fikk inntrykk av at de beveget seg ut i mer generelt terreng, og ikke spesifikt UV1. Hør 23.50.
For meg virker det som de snakker bredere. Uansett spennende om de tenker i slike baner for Ultimo også.

[Fornybar]

Det har de gjort i flere år i Ultimovacs

[TekBot]

Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma

• 80% overall survival rate at 24 months follow-up

Oslo, 13 October 2021: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical
…

Vis børsmeldingen

stage leader in immune stimulatory vaccines for cancer, announced continuing
positive topline results in its ongoing U.S.-based Phase I clinical trial
evaluating the Company’s universal cancer vaccine, UV1, in combination with the
checkpoint inhibitor pembrolizumab as a first-line treatment in metastatic
malignant melanoma. The trial had previously reached its primary endpoint of
safety and tolerability and at 24 months of follow-up continues to demonstrate
strong signs of clinical response.

In the Phase I trial, patients were treated initially for 14 weeks with UV1 in
combination with pembrolizumab. At the cut-off date of October 12, 2021, every
patient in the first cohort had been followed for at least 24-months from the
start of their treatment. The overall survival rate after two years of follow-up
was 80% in this first cohort of 20 patients. As previously announced, median
progression free survival for these patients was 18.9 months.

The 24-month follow-up data compares favorably with an earlier large-scale study
of pembrolizumab alone, which showed an overall survival rate of 58% after 24
months and median progression-free survival of 5.5-11.6 months*.

“The combination of UV1 and pembrolizumab has a strong safety profile and
provides a prolonged and effective clinical response in advanced melanoma,” said
Jens Bjørheim, Chief Medical Officer of Ultimovacs. “These two-year follow-up
data suggest that the way in which UV1 mobilizes the immune system provides
patients with lasting benefits.”

“We believe that UV1 will play a transformative role in the treatment of solid
tumors, elevating patients’ response rates in combination with checkpoint
inhibitors and providing long-term clinical benefits.” said Carlos de Sousa, CEO
of Ultimovacs. “We look forward to sharing more detailed results of this ongoing
study at a major clinical oncology meeting in 2022.”

The 12-month follow-up data from Ultimovacs’ Phase I trial can be accessed here
(https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=3823802&la
ng=en-GB&companycode=no-ulti&v=). For further information please also see the Q2
2021 financial report (http://asia.blob.euroland.com/press-releases-
attachments/1330542/ultimovacs-asa-q221-report.pdf).

• Keytruda package inserts and Robert C, Ribas A, Schachter J, et al.
  Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-
  year results from an open-label, multicentre, randomised, controlled, phase 3
  study. Lancet Oncol. 2019;20(9):1239-1251. doi:10.1016/S1470-2045(19)30388-2

                                ==ENDS==
  

About Ultimovacs
Ultimovacs is developing immune-stimulatory vaccines to treat a broad range of
cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 targets human
telomerase (hTERT), present in over 80% of cancers in all stages
of tumor growth. By directing the immune system to hTERT antigens, UV1 drives
CD4 helper T cells to the tumor to activate an immune system cascade and
increase anti-tumor responses. With a broad Phase II program, Ultimovacs aims to
clinically demonstrate UV1’s impact in multiple cancer types in combination with
other immunotherapies. Ultimovacs’ second technology approach, based on the
proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific
peptides and adjuvant in the same molecule and entered Phase I studies in 2021.

For further information, please see www.ultimovacs.com or contact:

Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com (mailto:carlos.desousa@ultimovacs.com)
Phone: +47 908 92507

Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com (mailto:hans.eid@ultimovacs.com)
Phone: +47 482 48632

Mary-Ann Chang, LifeSci Advisors
Email: mchang@lifesciadvisors.com (mailto:mchang@lifesciadvisors.com)
Phone: +44 7483 284 853

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Joachim Midttun, Finance
Manager at Ultimovacs ASA, on 13 October, 2021 at 08:00 CET.

Kilde

[enurs]

Var ikke dette ekstreme tall? 80% vs 58%.
Snakker vi Fast track her eller?

[AndyO]

Tror du må utvide ambisjonene et lite hakk👊.

[theroger]

Ultimovacs melder om positive resultater

Gjelsten og Hagens biotekselskap Ultimovacs stiger kraftig på Børsen – aldri...

Oslo Børs reagerer kraftig på vaksine-studie: Enormt utslag for superinvestorer

Ultimovacs presenterer positive oppfølgingsdata

Cancer Vaccine-Pembrolizumab Combination Study Updated

Bjørn Rune Gjelsten til himmels med Ultimovacs

[polygon]

Bare OS altså, men hvilken OS!

Null døde de siste seks månedene!

NÅ kan vi begynne å spekulere i om det har vært ytterligere en CR!

[h3nk1]

@h3nk1

What will Sweden do?

[Fartin]

Er det andre komonasjonsbehandlinger der ute under utvikling som vi kan måle mot?

[hybrid]

[theroger]

FOCUS studien ute på Clinical Trials

Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or...

[alfred_e_neuman]